Callisto Pharmaceuticals develops novel therapeutics for cancer. At present we have three products in development:

  • Atiprimod is an orally available small molecule drug that displays a multiplicity of anti-cancer mechanistic activities. The drug is presently in Phase II development for advanced carcinoid cancer and has potential in several other cancers, including liver and colon as well as mantle cell lymphoma.
  • L-Annamycin is a liposome nanoparticle formulation of annamycin, a second generation anthracycline. It has been developed to address shortcomings with the current generation anthracycline drugs to treat relapsed acute leukemia patients. L-Annamycin has the potential to work against anthracycline-resistant tumors and is expected to have reduced cardiotoxicity. The compound is currently in Phase I/IIa trials for both adults and children with relapsed or refractory acute leukemia.